<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62255">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295462</url>
  </required_header>
  <id_info>
    <org_study_id>EPCentCare</org_study_id>
    <secondary_id>01GY1335A</secondary_id>
    <secondary_id>01GY1335B</secondary_id>
    <secondary_id>01GY1335C</secondary_id>
    <nct_id>NCT02295462</nct_id>
  </id_info>
  <brief_title>Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial</brief_title>
  <acronym>EPCentCare</acronym>
  <official_title>Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Witten/Herdecke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Up to 90% of nursing home residents with dementia experience behavioural and
      psychological symptoms like apathy, agitation, and anxiety. According to analyses of
      prescription prevalence in Germany, antipsychotic drugs seem to be prescribed as first line
      treatment of neuropsychiatric symptoms in persons with dementia. A huge number is prescribed
      for inappropriate reasons and too long without regular review. The use of antipsychotics is
      associated with adverse events like increased risk of falling, stroke, and mortality. This
      study aims to investigate whether a person-centered care approach developed in the United
      Kingdom can be adapted and implemented in German nursing homes. The aim of the investigators
      trial is to achieve a clinically relevant reduction of the proportion of residents with alt
      least one antipsychotic drug prescription.

      Methods/Design: Cluster-randomised controlled trial comparing an intervention group (two-day
      initial skill training on person-centred care and on-going training and support programme)
      with a control group receiving optimised usual care. Both study groups will receive a
      medication review by an experienced psychiatrist with feedback to the prescribing physician.
      Overall, 36 nursing homes from East, North and West Germany will be included and randomised.
      The primary outcome is defined as the proportion of residents receiving at least one
      antipsychotic medication at 12 months. Secondary outcomes are residents' quality of life,
      behavioural and psychological symptoms of dementia as well as safety parameters like falls
      and fall-related medical attention. Cost parameters will be collected and process evaluation
      will be performed alongside the trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of residents receiving at least one antipsychotic medication after 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residents' quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Will be measured with the QoL-AD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioural and psychological symptoms of dementia</measure>
    <time_frame>12 months</time_frame>
    <description>Will be measured with the CMAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs within trial period</measure>
    <time_frame>12 months</time_frame>
    <description>Cost parameters will be collected alongside the trial on intervention-related components as well as outcome-related components. Costs which are explicitly trial-associated will not be taken into account for cost analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falls and fall-related medical attention</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical restraints within study period</measure>
    <time_frame>12 months</time_frame>
    <description>Physical restraints will be assessed retrospectively by data extraction from residents' records- The following devices will be assessed: bilateral bedrails, belts, fixed tables, and other measures limiting free body movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median daily dose of antipsychotics in chlorpromazine equivalents within study period</measure>
    <time_frame>12 months</time_frame>
    <description>Each resident's daily dose of antipsychotic drugs will be translated into chlorpromazine daily equivalents.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Process evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Different methods will be used for data collection: investigators documentation, questionnaires on staff knowledge and self-efficacy, structured interviews and in depth-interviews with staff.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2340</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Person-centered Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medication Review + Person-centered Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimised Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medication Review</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Person-centered Care</intervention_name>
    <description>Medication Review + Person-centered Care</description>
    <arm_group_label>Person-centered Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimised Treatment</intervention_name>
    <description>Medication Review only</description>
    <arm_group_label>Person-centered Care</arm_group_label>
    <arm_group_label>Optimised Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        On cluster level

        Inclusion Criteria:

          -  nursing homes with at least 50 residents

        Exclusion Criteria:

          -  other ongoing trial in the institution

        On individual level

        Inclusion Criteria:

          -  all residents within a cluster are eligible to participate in the study

        Exclusion Criteria:

          -  diagnoses of schizophrenia, schizoaffective psychosis, or other forms of primary
             psychosis

          -  respite care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Meyer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martin-Luther-Universität Halle-Wittenberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriele Meyer, Prof. Dr.</last_name>
    <phone>+49345</phone>
    <phone_ext>5574498</phone_ext>
    <email>gabriele.meyer@medizin.uni-halle.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steffen Fleischer, Dr.</last_name>
    <phone>+49345</phone>
    <phone_ext>5574133</phone_ext>
    <email>steffen.fleischer@medizin.uni-halle.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universität Witten/Herdecke</name>
      <address>
        <city>Witten Herdecke</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58448</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Sönnichsen, Prof. Dr.</last_name>
      <phone>+49 2302926741</phone>
      <email>andreas.soennichsen@uni-wh.de</email>
    </contact>
    <contact_backup>
      <last_name>Susanne Löscher, MSc</last_name>
      <phone>+49 2302926784</phone>
      <email>susanne.loescher@uni-wh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Horst C Vollmar, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Meyer, Prof. Dr.</last_name>
      <phone>+49</phone>
      <phone_ext>3455574498</phone_ext>
      <email>gabriele.meyer@medizin.uni-halle.de</email>
    </contact>
    <contact_backup>
      <last_name>Steffen Fleischer, Dr.</last_name>
      <phone>+49</phone>
      <phone_ext>5574133</phone_ext>
      <email>steffen.fleischer@medizin.uni-halle.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Luebeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sascha Köpke, Prof. Dr.</last_name>
      <phone>+49 4515005467</phone>
      <email>sascha.koepke@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Eva-Maria Fick, Dr.</last_name>
      <phone>+49 4515005918</phone>
      <email>eva-maria.fick@uksh.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>November 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Gabriele Meyer</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>nursing homes</keyword>
  <keyword>person-centered care</keyword>
  <keyword>inappropriate prescriptions</keyword>
  <keyword>cluster-randomised controlled trial</keyword>
  <keyword>antipsychotic drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
